Genovis (GENO) investor relations material

Executive summary

• Net sales for Q4 2025 reached SEK 40,252 thousand, up 44% year-over-year (58% adjusted for currency), driven by a major order from a global pharmaceutical company and a recovery in customer activity, especially in the US biotech segment.

• Full-year net sales were SEK 128,946 thousand, reflecting 17% growth (23% currency-adjusted) in the core enzyme business, with strong organic growth after excluding divested antibody business and non-recurring license revenues.

• Acquisition of the remaining 75% of Sequrna AB in July 2025 expanded the product portfolio into genomics and contributed to increased personnel and integration costs.

Financial highlights

• Q4 EBITDA was SEK 11,737 thousand (up from 7,771), with an EBITDA margin of 29%.

• Full-year EBITDA reached SEK 33,558 thousand (up from 30,688), negatively impacted by SEK -5,116 thousand in currency effects and SEK 1,287 thousand in transaction costs for the Sequrna acquisition.

• Q4 earnings per share were SEK 0.10 (up from 0.07); full-year EPS was SEK 0.36 (down from 0.50 due to prior year’s one-off gains).

• Cash flow from operating activities for Q4 was SEK 15,895 thousand; full-year cash flow from operations was SEK 32,022 thousand.

• Gross margin remained strong at 88.9% for Q4 and 89.3% for the year.

Outlook and guidance

• Management expects continued growth, supported by a strengthened position in antibody conjugation and genomics, and increasing customer activity in key markets.

• The company is well positioned for further advances in new products and sales in 2026, though geopolitical and macroeconomic uncertainties persist.